- Home
- PSTV
as 07-26-2024 4:00pm EST
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 9.9M | IPO Year: | N/A |
| Target Price: | $8.00 | AVG Volume (30 days): | 62.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.97 - $3.21 | Next Earning Date: | 08-12-2024 |
| Revenue: | $6,084,000 | Revenue Growth: | 733.42% |
| Revenue Growth (this year): | 5.21% | Revenue Growth (next year): | -15.15% |
Stock Insider Trading Activity of PLUS THERAPEUTICS Inc. (PSTV)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lenk Robert P | PSTV | Director | May 8 '24 | Buy | $2.04 | 4,167 | $8,500.68 | 29,327 | SEC Form 4 |
| Sims Andrew John Hugh MacIntyre | PSTV | Chief Financial Officer | May 8 '24 | Buy | $2.04 | 4,902 | $10,000.08 | 5,717 | SEC Form 4 |
| Petersen Greg | PSTV | Director | May 8 '24 | Buy | $2.04 | 12,255 | $25,000.20 | 36,421 | SEC Form 4 |
| Clowes Howard | PSTV | Director | May 8 '24 | Buy | $2.04 | 9,804 | $20,000.16 | 21,497 | SEC Form 4 |
| Hawkins Richard J | PSTV | Director | May 8 '24 | Buy | $2.04 | 4,902 | $10,000.08 | 4,903 | SEC Form 4 |
| HEDRICK MARC H | PSTV | Chief Executive Officer | May 8 '24 | Buy | $2.04 | 12,255 | $25,000.20 | 12,425 | SEC Form 4 |
| HEDRICK MARC H | PSTV | Chief Executive Officer | Nov 20 '23 | Sell | $1.96 | 2,068 | $4,052.66 | 170 | SEC Form 4 |
| Lenk Robert P | PSTV | Director | Nov 15 '23 | Buy | $1.77 | 1,000 | $1,770.00 | 24,160 | SEC Form 4 |
| Lenk Robert P | PSTV | Director | Nov 15 '23 | Buy | $1.95 | 1,000 | $1,950.00 | 25,160 | SEC Form 4 |
| Lenk Robert P | PSTV | Director | Nov 8 '23 | Buy | $1.65 | 5,000 | $8,250.00 | 12,961 | SEC Form 4 |
| Lenk Robert P | PSTV | Director | Nov 8 '23 | Buy | $1.59 | 4,199 | $6,676.41 | 17,160 | SEC Form 4 |
Latest PLUS THERAPEUTICS Inc. News
PSTV Breaking Stock News: Dive into PSTV Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
GlobeNewswire
24 days ago
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
CNW Group
2 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Simply Wall St.
2 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
2 months ago
Seoul says it will resume loudspeaker propaganda against North
Simply Wall St.
2 months ago
It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
Simply Wall St.
2 months ago
OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
Barrons.com
2 months ago
Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
Compare PSTV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PSTV PLUS THERAPEUTICS Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.